# OnCo record candel-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/candel-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "candel-therapeutics" ;
  schema:name "Candel Therapeutics"@en ;
  schema:description "Candel makes viral immunotherapies injected into tumours to trigger an immune attack. Its lead product, aglatimagene, improved disease-free survival when added to radiotherapy in localised prostate cancer in a phase 3 trial, and a US approval filing is planned for late 2026."@en ;
  schema:url <https://onco.cc/companies/candel-therapeutics/>, <https://candeltx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://candeltx.com/>, <https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm>, <https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-ex99_1.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:drugs <https://onco.cc/drugs/aglatimagene-besadenovec/> ;
  onco:trials <https://onco.cc/trials/nct01436968/>, <https://onco.cc/trials/nct02768363/>, <https://onco.cc/trials/nct07332000/>, <https://onco.cc/trials/nct04495153/> .